A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation

Journal of Cystic Fibrosis ◽

10.1016/j.jcf.2020.07.023 ◽

2020 ◽

Author(s):

Jane C. Davies ◽

Isabelle Sermet-Gaudelus ◽

Lutz Naehrlich ◽

R. Scott Harris ◽

Daniel Campbell ◽

...

Keyword(s):

Cystic Fibrosis ◽

Efficacy And Safety ◽

Residual Function ◽

Phase 3 ◽

Double Blind ◽

Parallel Group Study ◽

Parallel Group

Download Full-text

A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation

Journal of Cystic Fibrosis ◽

10.1016/j.jcf.2020.11.003 ◽

2020 ◽

Cited By ~ 1

Author(s):

Edward F. McKone ◽

Emily A. DiMango ◽

Sivagurunathan Sutharsan ◽

Tara Lynn Barto ◽

Daniel Campbell ◽

...

Keyword(s):

Cystic Fibrosis ◽

Phase 3 ◽

Double Blind ◽

Parallel Group Study ◽

Parallel Group

Download Full-text

Efficacy and safety of rotigotine in Japanese patients with restless legs syndrome: a phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group study

Sleep Medicine ◽

10.1016/j.sleep.2013.07.007 ◽

2013 ◽

Vol 14 (11) ◽

pp. 1085-1091 ◽

Cited By ~ 13

Author(s):

Yuichi Inoue ◽

Tetsuo Shimizu ◽

Koichi Hirata ◽

Naohisa Uchimura ◽

Jun Ishigooka ◽

...

Keyword(s):

Restless Legs Syndrome ◽

Japanese Patients ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Restless Legs ◽

Parallel Group Study ◽

Parallel Group

Download Full-text

Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction

American Heart Journal ◽

10.1016/j.ahj.2020.10.052 ◽

2021 ◽

Vol 231 ◽

pp. 121-127 ◽

Cited By ~ 1

Author(s):

C. Michael Gibson ◽

John J.P. Kastelein ◽

Adam T. Phillips ◽

Philip E. Aylward ◽

Megan K. Yee ◽

...

Keyword(s):

Myocardial Infarction ◽

Acute Myocardial Infarction ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Parallel Group Study ◽

Parallel Group

Download Full-text

A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfw408 ◽

2017 ◽

pp. gfw408 ◽

Cited By ~ 8

Author(s):

Masafumi Fukagawa ◽

Keitaro Yokoyama ◽

Takashi Shigematsu ◽

Takashi Akiba ◽

Akifumi Fujii ◽

...

Keyword(s):

Secondary Hyperparathyroidism ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Parallel Group Study ◽

Parallel Group ◽

Amg 416

Download Full-text

Rationale and design of the MODIFY study: A phase 3 multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease

Molecular Genetics and Metabolism ◽

10.1016/j.ymgme.2019.11.423 ◽

2020 ◽

Vol 129 (2) ◽

pp. S159

Author(s):

Christoph Wanner ◽

Derralynn Hughes ◽

Virginia Kimonis ◽

Juan Politei ◽

Nurcan Üçeyler ◽

...

Keyword(s):

Fabry Disease ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Parallel Group Study ◽

Parallel Group

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717995300.793478299 ◽

2013 ◽

Author(s):

Altaf Mangera

Keyword(s):

Low Dose ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Orally Disintegrating Tablet ◽

Parallel Group Study ◽

Parallel Group

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727328077.793564275 ◽

2019 ◽

Author(s):

Ladislav Senolt

Keyword(s):

Rheumatoid Arthritis ◽

Active Rheumatoid Arthritis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Parallel Group

Download Full-text

Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial

Advances in Therapy ◽

10.1007/s12325-020-01603-8 ◽

2021 ◽

Vol 38 (4) ◽

pp. 1889-1903

Author(s):

Yuqin Song ◽

Hui Zhou ◽

Huilai Zhang ◽

Wei Liu ◽

Yuerong Shuang ◽

...

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Large B Cell Lymphoma ◽

Parallel Group ◽

Large B Cell

Download Full-text

Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation

Bone Marrow Transplantation ◽

10.1038/sj.bmt.1702479 ◽

2000 ◽

Vol 26 (2) ◽

pp. 203-210 ◽

Cited By ~ 44

Author(s):

TR Spitzer ◽

CJ Friedman ◽

W Bushnell ◽

SR Frankel ◽

J Raschko

Keyword(s):

Total Body Irradiation ◽

Nausea And Vomiting ◽

Efficacy And Safety ◽

Double Blind ◽

Parallel Group Study ◽

Parallel Group ◽

Total Body ◽

Oral Ondansetron

Download Full-text

Phase 3, single-center, sequential and parallel-group, double-blind, randomized study evaluating the efficacy and safety of Fexofenadine Hydrochloride 180 mg (Allegra®/Telfast®) versus placebo in subjects suffering from Allergic Rhinitis with symptoms aggravated in presence of pollutants: analysis of individual symptom scores

World Allergy Organization Journal ◽

10.1016/j.waojou.2020.100266 ◽

2020 ◽

Vol 13 (8) ◽

pp. 100266

Author(s):

Anne K. Ellis ◽

Margarita Murrieta-Aguttes ◽

Sandy Furey ◽

Christopher Carlsten

Keyword(s):

Allergic Rhinitis ◽

Randomized Study ◽

Efficacy And Safety ◽

Single Center ◽

Phase 3 ◽

Double Blind ◽

Parallel Group ◽

Symptom Scores

Download Full-text